anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants assigned to treatment group that includes case management will receive an initial assessment to determine their strengths and needs. The participant will then work collaboratively with their case manager to connect to community resources to meet his needs. To do so, the case manager will meet with the participant using the following schedule: Months 1-2: intervention in the form of weekly face-to-face meeting with a case manager, plus a weekly phone call from a case manager; Months 3-4: intervention in the form of face-to-face meeting every other week, plus a weekly phone call; Months 5-6: intervention in the form of face-to-face meeting once a month, plus a weekly phone call.
A total of 418 subjects in clinical studies of micafungin for injection were 65 years of age and older, and 124 subjects were 75 years of age and older. No overall differences in safety and effectiveness were observed between these subjects and younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out. The exposure and disposition of a 50 mg micafungin for injection dose administered as a single 1-hour infusion to 10 healthy subjects aged 66 to 78 years were not significantly different from those in 10 healthy subjects aged 20 to 24 years. No dose adjustment is necessary for the elderly.

Each 50 mg/50 mL Galaxy container of Micafungin in Sodium Chloride Injection contains 200 mg of sodium, each 100 mg/100 mL Galaxy container of Micafungin in Sodium Chloride Injection contains 400 mg of sodium, and each 150 mg/150 mL Galaxy container of Micafungin in Sodium Chloride Injection contains 600 mg of sodium. The geriatric population may respond with a blunted natriuresis to salt loading. This may be clinically important with regard to such diseases as congestive heart failure and other conditions requiring restricted sodium intake [see Warnings and Precautions (5.6)].
Participants in this group will complete 3 resistance training sessions per week for 6 weeks (18 sessions total). During each resistance training session, participants will perform 3 sets of bilateral leg-extensions (performed with both legs) to volitional failure (likely 8-12 repetitions) using 80% of their 1-repetition maximum (the most weight they are able to perform 1 complete repetition with, but not 2).
Zmax (azithromycin extended release) for oral suspension contains the active ingredient azithromycin (as azithromycin dihydrate), an azalide, a subclass of macrolide antibiotics. Azithromycin has the chemical name (2R,3S,4R,5R,8R,10R,11R,12S,13S,14R)13-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-α-L-ribo-hexopyranosyl) oxy]-2-ethyl-3,4,10-trihydroxy-3,5,6,8,10,12,14-heptamethyl-11-[[3,4,6-trideoxy-3- (dimethylamino)-β-D-xylo-hexopyranosyl]oxy]-1-oxa-6-azacyclopentadecan-15-one. Azithromycin is derived from erythromycin; however, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring. Its molecular formula is C38H72N2O12, and its molecular weight is 749.0. Azithromycin has the following structural formula:

Azithromycin, as the dihydrate, is a white crystalline powder with a molecular formula of C38H72N2O12•2H2O and a molecular weight of 785.0.

Zmax is a single-dose, extended release formulation of microspheres for oral suspension containing azithromycin (as azithromycin dihydrate) and the following excipients: glyceryl behenate, poloxamer 407, sucrose, sodium phosphate tribasic anhydrous, magnesium hydroxide, hydroxypropyl cellulose, xanthan gum, colloidal silicon dioxide, titanium dioxide, artificial cherry flavor, and artificial banana flavor.

Note: Each bottle of Zmax 2 g for oral suspension contains approximately 148 mg of sodium and 19 g of sucrose. Constituted Zmax oral suspension contains approximately 2 mg/mL of sodium and 0.26 g/mL of sucrose.
Dosage adjustments of famotidine tablets are recommended for patients with moderate to severe renal impairment (creatinine clearance less than 60 mL/min) [see Use in Specific Populations (8.6)]. Table 2 shows the recommended maximum dosage of famotidine 20 mg or 40 mg tablets for patients with renal impairment, by indication. Use the lowest effective dose. Some dosage adjustments may require switching to other formulations of famotidine (e.g., oral suspension, lower dose tablet). 

Table 2: Recommended Maximum Dosage of Famotidine Tablets in Adult and Pediatric Patients 40 kg and Greater with Moderate and Severe Renal Impairment 

a An alternate dosage regimen is 10 mg once daily. Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation. 

b Dosage adjustments for renal impairment are provided for both dosing regimens (20 mg twice daily and 40 mg twice daily) which showed effectiveness for the treatment of erosive esophagitis in clinical trials [see Clinical Studies (14.4)]. 

c In pediatric patients, the safety and effectiveness of famotidine tablets have not been established for the reduction of the risk of duodenal ulcer recurrence or for treatment of pathological hypersecretory conditions [see Use in Specific Populations (8.4)]. 

d Doses required to treat pathological hypersecretory conditions may exceed the maximum doses evaluated in patients with impaired renal function. The risk for increased adverse reactions in renally impaired patients treated with famotidine tablets for pathological hypersecretory conditions is unknown. 

e Recommended dosage regimen is 10 mg every other day. Since 20 mg or 40 mg tablet strength cannot be used for this dosage regimen, use an alternate famotidine formulation.
For pediatric patients at least 3 months old and weighing at least 3.5 kg and adults who cannot swallow capsules or tablets, the capsule contents may be administered with a small amount (1 to 2 teaspoons) of food. Use of infant formula for mixing should only be considered for those young infants who cannot reliably consume solid foods. Patients and caregivers should be instructed to open the capsule carefully to avoid spillage or dispersion of the capsule contents into the air. The capsule should be held horizontally over a small container and carefully twisted to open. For patients able to tolerate solid foods, the entire capsule contents should be gently mixed with an age-appropriate soft food, such as applesauce, grape jelly, or yogurt, in the small container. For young infants receiving the capsule sprinkle-infant formula mixture, the entire capsule contents should be gently mixed into 2 teaspoons of reconstituted room temperature infant formula in a small container by carefully stirring with a small spoon, and then drawing up the mixture into a 10 mL oral dosing syringe for administration. After administration of the efavirenz-food or -formula mixture, an additional small amount (approximately 2 teaspoons) of food or formula must be added to the empty mixing container, stirred to disperse any remaining efavirenz residue, and administered to the patient. The efavirenz-food or -formula mixture should be administered within 30 minutes of mixing. No additional food should be consumed for 2 hours after administration of efavirenz.
Similar pre-stored medical data sets are identified by comparison with the current case data set. A current case data set is provided and includes radiology data of the patient. A plurality of pre-stored medical data sets is provided, each pre-stored medical data set including radiology data of other patients. Each case data set is evaluated according to a predefined AI-based approach to obtain a number of definitive features for the case data set. The conclusive feature of the current case dataset is compared to the conclusive feature of each of the pre-stored medical datasets to identify a plurality of pre-stored medical datasets that are most similar to the current case dataset. Outputting the identified plurality of most similar pre-stored medical data sets.
A breathable biological face covering comprising a fabric material and an anti-pathogen substance on the fabric material. The anti-pathogen substance comprises a lactoferrin protein. The amount of lactoferrin protein on the fabric material may be in the range of 0.6–1.5 grams/m2 of fabric material. Another embodiment is a lactoferrin composition comprising an aqueous fluid at pH <7.0 and lactoferrin protein mixed in the aqueous fluid at a concentration of 0.6–1.5 grams per liter. This lactoferrin composition may be administered into the respiratory tract. This composition could be useful against respiratory microbial pathogen, such as influenza virus or coronavirus.
Cognitive Processing Therapy (CPT) is a manual-guided therapy that incorporates cognitive processing techniques to relieve PTSD symptoms (Resick et al., 2016). Each group session will be 90 to 120 minutes long and will be occur once each week for 12 weeks.
SX-682 will be administrated at the same dose the participant was administered in monotherapy and will be administered in a 6 week cycle that includes 2 i.v. infusions of pembrolizumab on days 1 and 22 of each cycle, for a total of up to 17 cycles. Once the highest safe dose of SX-682 in combination therapy with pembrolizumab is determined, participants will be enrolled in an expansion phase at that SX-682 dose with pembrolizumab combination therapy.
Participants will place their non-dominant hand into water cooled by a refrigeration unit (NESLAB RTE 7 Digital One, Thermo Scientific Co., Massachusetts, USA) that circulates water continuously to maintain a constant temperature of 6 degrees Celsius (males) or 8 degrees Celsius (females). The participant will place his or her hand in the cooled water for 60 seconds followed by a 30 second break in which the participant will remove his or her hand from the water. This will occur 4 times for a total immersion time of 240 seconds.
The safety and effectiveness of PERTZYE for the treatment of exocrine pancreatic insufficiency have been established in pediatric patients.

Use of PERTZYE for this indication is supported by a randomized, double-blind, placebo-controlled, crossover study of 24 pediatric patients, 8 years and older with exocrine pancreatic insufficiency due to cystic fibrosis. The safety in pediatric patients was similar to that observed in adult patients [see Adverse Reactions (6.1) and Clinical Studies (14)].

Dosages exceeding 6,000 lipase units/kg/meal have been reported postmarketing to be associated with fibrosing colonopathy and colonic strictures in pediatric patients less than 12 years of age. If there is a history of fibrosing colonopathy, monitor patients during treatment with PERTZYE because some patients may be at risk of progressing to stricture formation. Do not exceed the recommended dosage of either 2,500 lipase units/kg/meal, 10,000 lipase units/kg/day, or 4,000 lipase units/g fat ingested/day in pediatric patients greater than 12 months of age without further investigation [see Dosage and Administration (2.1) and Warnings and Precautions (5.1)].

Crushing or chewing PERTZYE capsules or mixing the capsule contents in foods having a pH greater than 4.5 can disrupt the protective enteric coating on the capsule contents and result in early release of enzymes, irritation of the oral mucosa, and/or loss of enzyme activity. Instruct the patient or caregiver of the following: consume sufficient liquids (juice, water, breast milk, or formula) to ensure complete swallowing, and visually inspect the mouth of pediatric patients less than 12 months of age to ensure that no drug is retained in the mouth and irritation of the oral mucosa has not occurred [see Dosage and Administration (2.3) and Warnings and Precautions (5.2)].
This invention is directed to a plastic orthodontic appliance having projecting structure extending outwardly from a bonding base. The projecting structure includes a broadened outer extremity and undercuts proximate the outer extremity which form mechanical bonds with a bonding adhesive. In one application, a plurality of appliances in the form of slotted brackets is provided for cooperating with an archwire to apply corrective forces to a patient's teeth on which the brackets are mounted. Another aspect of the invention concerns a method of making plastic orthodontic appliances suitable for mechanical bonding. The method includes molding a plastic orthodontic appliance having undeformed projecting structure and subsequently softening and compressing the outer extremity of the projecting structure to form undercuts. In a preferred embodiment, the projecting structure is a plurality of posts.
PURPOSE: A drug delivery composition including bio compatible hyaluronic acid crosslinking materials is provided to show long-lasting and to reduce manufacturing cost. CONSTITUTION: A drug delivery composition contains protein drug or antiphlogistics in a carrier or a supporter which essentially includes polysaccharides used as a pharmaceutical formulation or for tissue engineering. The drug delivery composition is composed of crosslinking material of the hyaluronic acid which is polysaccharide and the bio compatible polymer in order to control and regulate the quantity of emission. The molecular weight of the hyaluronic acid is 30,000-3,000,000 daltons(Da). A drug delivery composition comprises hyaluronic acid hydrogel which is cross-linked by the amidation of bio compatible polymer or bio compatible polymer different from the carboxyl group of the hyaluronic acid by using EDC(1-Ethyl-3-(3-dimethylaminopropyl)-carbodiimide) in 0.5-10 wt% of solution of the hyaluronic acid, protein drug or non-steroidal anti-inflammatory agent. The bio compatible polymer is a homopolymer of lactic acid in a range of the molecular weight 6,000-100,000, copolymers derivative of the lactic acid and glycolic acid or a mixture thereof. [Reference numerals] (AA) Hyaluronic acid; (BB) Cross-linked hyaluronic acid/gellatin; (CC) Cross-linked hyaluronic acid/chitosan; (DD) Cross-linked hyaluronic acid/collagen
The whole intervention has 24 sessions. Children will play with the game two times a week, each lasting 15 minutes, over a period of 12 weeks. Each session stimulates two skills (one cognitive and one non-cognitive skills) and has eight activities with increasing levels of difficulty.
1. Technical Result Increase in efficiency of treatment of p38 kinase mediated disorders.         2. Essence A compounds of the formula wherein R1, R2, R3 and R4 are described in the specification or a tautomer thereof or a pharmaceutically-acceptable salt; when treating p38 kinase mediated disorders, the patient is introduced the mentioned composition in therapeutically acceptable amount; production of the mentioned composition or a tautomer thereof or a pharmaceutically-acceptable salts are effected by processing the corresponding substituted ketone with acylhydrazine.          3. Field of Application Medicine.                Tables: 13
Five placebo pills a time and three times a day. One treatment period including 8 weeks.
PURPOSE:To obtain a gradual releasing preparation excellent in gradual release effect and simple to prepare, by impregnating a powder mixture consisting of a thermoplastic resin powder and a cellulose powder with a volatile substance. CONSTITUTION:A gradual releasing preparation excellent in gradual release effect is obtained by impregnating a powder mixture consisting of a thermoplastic resin (e.g.; an ethylene/vinyl acetate copolymer) powder (a) and a cellulose powder (b) with a volatile substance (e.g.; fragrance or insecticide) (c). A method for preparing this gradual releasing preparation is not especially limited. For example, when the component (c) is liquid, said component is directly infiltrated in either one of the component (a) and the component (b) and both of them are subsequently mixed and, when the component (c) is solid, said component (c) is dissolved in a solvent before the same process is taken or the component (c) are infiltrated in the powder mixture of the components (a), (b). By this method, the gradual releasing preparation can be prepared. The mixing ratio of the component (a) and the component (b) is pref. 1:20-100:1 on a wt. basis. The average particle size of the component (a) is pref. 1-1,000mum.
Placebo-matching TDV, 0.5mL, subcutaneous (SC) injection on Day 1 (Month 0) and Day 90 (Month 3). Participants eligible for Booster Phase received placebo matching TDV, SC injection, based on the randomization on Day 1 (Month 0).
With nearly one million cases of dementia in France in 2010, Alzheimer's disease (AD) and related syndromes are a major public health issue. The lake of drug for treatment or preventing AD, health related quality of life (HRQoL) became an essential criterion of evaluation to assess the treatment strategies of patients. Generic HRQoL tools are generally less sensitive for a given disease. That is why other specific tools for AD have been developed. None of them was validated in French. The aim of this study was therefore, after a review of the literature, to achieve a cross-cultural adaptation and psychometric validation of the "Quality of Life in Alzheimer's Disease" (QoL-AD) and "Dementia Quality of Life" (DQoL). These two questionnaires were selected because they were the most popular in English- language literature for this disease.This study concerned a total of 155 patient-caregiver pairs recruited from six French hospitals and a Francophone Swiss center.

Patients had a confirmed diagnosis of AD (mild stage to moderate: Mini Mental State Examination ≥ 10). QoL-AD and DQoL were administered by an interviewer. The caregiver sheet of QoL-AD was self-administered. Cross-cultural adaptation and psychometric validation have been carried out for these two questionnaires. First step: the linguistic adaptation will be performed according to the latest available methodology: that of the " Institute for Work and Health ", as recommended 6 phases. Second step: the psychometric validation will be done after a multicentric study, cross repeated at weekly intervals for the validation phase , with two longitudinal points for the assessment phase of sensitivity to change. Analysis of the results will help define the applicability criteria and psychometric acceptability to know the validity of the adapted instrument that is to say, its content validity , validity of perceived, validity of structure, validity of agreement , its discriminative ability , reliability explored by internal consistency and stability over time. Longitudinal follow-up of patients is expected to also assess the sensitivity to change .
VLCKD (780 kcal/day) low in carbohydrates (\<50 g per day) and lipids (only 10 g of olive oil per day) for 45 days. High-biological-value protein preparations will be given four times per day, based on whey protein.
This is a randomized, double-blind, placebo-controlled, multi-center study to evaluate the efficacy and safety of two dosing regimens of MN-001 in patients with Interstitial Cystitis (IC). Patients will be screened for study eligibility within seven to nine days of randomization. Eligible patients will be randomized in a 1:1:1 ratio to receive either 500 mg MN-001 bid, 500 mg MN-001 once daily or placebo. Patients will be dispensed study drug beginning at Baseline (Visit 2) and will return to the study center for Visit 3 (28 days ± 2 days after Baseline), and Visit 4 (56 days ± 2 days after Baseline), at end of study for safety and efficacy assessments. The patient will be contacted by telephone at Week 6 (42 days ± 2 days after Baseline) for an interim follow up. Study drug will be dispensed at Visits 2 and 3. Safety assessments will include adverse events, physical examinations, clinical laboratory testing, and changes in vital signs. Efficacy assessments include percentage of patients at least "moderately improved" for each treatment group using the patient reported Global Response Assessment (GRA) (see Appendix 1). Secondary assessments include a decrease in bladder pain/urgency based on change in the patient rating from baseline to endpoint using the GRA (see Appendix 1), modified Pelvic Pain and Urgency/Frequency (PUF) Patient Symptom Scale (see Appendix 2) and the O'Leary Sant IC Symptom and Problem Index.
Information on a nucleotide sequence is processed by receiving request information of an object or service. A first processor searches and retrieves from a first memory area positional information corresponding to information on classification of the object or service. The positional information represents a position in a nucleotide sequence. The retrieved positional information is transmitted to a second processor which accesses a second memory area storing polymorphism information regarding the individual. Polymorphism information is received based on the transmitted positional information. The received polymorphism information is output to a user. The user includes a third processor which accesses a third memory area. The third memory area is searched to retrieve, semantic information based on the transmitted polymorphism information. The semantic information is output to a device that utilizes the semantic information or information corresponding to the semantic information for a provision of the object or service.
Subjects on a 1200 mg sodium diet are given 2300 mg sodium in the form of slow sodium tablets to bring them back up to a normal salt intake. Subjects then cross-over to the low sodium condition in the second half of the study.
Conventional ventilation control is set 30 minutes before Nursing 1 after randomization. Ventilator is switch to full closed-loop ventilation (INTELLIVENT-ASV) 30 minutes before Nursing 2.
Participants will be screened based on Fibroblast Growth Factor Receptor Inhibitor Clinical Trial Assay (FGFRi CTA) to determine molecular eligibility and participants who meet molecular eligibility criteria will be eligible for full study screening. Participants enrolled in the study (treated with prior anti-programmed cell death protein PD-\[L\] 1 agent) will swallow erdafitinib tablets orally at a starting dose of 8 milligram (mg), once daily for 21 days in a 21-day cycle until disease progression, intolerable toxicity, withdrawal of consent or decision by the investigator to discontinue treatment. Dose adjustment are based on phosphate level and observed toxicity (adverse events \[AEs\]). Participants who enter in Long-term extension (LTE) phase will continue to receive the erdafitinib tablet as per investigator's decision.
Recent small subcortical infarction (RSSI) is defined as small deep infarctions in the territory of perforating arteries with maximum axial diameters (MAD) of less than 20 mm. In this study, RSSIs in the territories of lenticulostriate area, pons are enrolled.